Patent US4656027A successfully refreshed from Google Patents.
US4656027A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical mixture
Assignee: Astra Lakemedel AB
•
Filing: 1984-11-02
•
Granted: 1987-04-07
•
Expires: 2004-11-02
Abstract
Abstract The present invention is concerned with masking bad taste in pharmaceutical preparations containing encapsulated drugs with bad taste. The object of the invention is achieved by including a basic substance in the preparation.
Inventors
- 👤 Rolf I. Sjoovist
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 17:06
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/14; A61K9/0087; A61K9/0095; A61K31/00; A61K31/33; A61K31/395; A61K31/41; A61K31/425; A61K31/429; A61K31/43; A61K9/16; A61K9/1605; A61K9/1611; A61K9/48; A61K9/50; A61K9/5005; A61K9/5021; A61K9/5036; A61K9/5042; A61K9/5047
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
135 words
A method for preparing a dry powder for use as a pharmaceutical preparation which comprises mixing a pharmaceutically acceptable basic substance selected from the group consisting of sodium bicarbonate, disodium mono hydrogenphosphate, dipotassium hydrogenphosphate, trisodium citrate, magnesium dihydroxide and trizma with a bad tasting drug, said drug being in a form insoluble at high pH, and said basic substance being present in a mole ratio of basic substance to drug of 0.2-10, and encapsulating the mixture in a material consisting essentially of a water insoluble polymer selected from the group consisting of ethylcellulose, polyvinyl acetate, polyvinyl chloride and a copolymer of dimethylaminoethyl methacrylate and methyl methacrylate, wherein the encapsulated material is present in an amount that allows bioavailability and which in combination with the basic substance is sufficient to mask the taste of the drug.
Claim 2
Independent Claim
135 words
A method for preparing a dry powder for use as a pharmaceutical preparation which comprises mixing a pharmaceutically acceptable basic substance selected from the group consisting of sodium bicarbonate, disodium mono hydrogenphosphate, dipotassium hydrogenphosphate, trisodium citrate, magnesium dihydroxide and trizma with a bad tasting drug, said drug being in a form insoluble at high pH, and said basic substance being present in a mole ratio of basic substance to drug of 0.2-10, and encapsulating the mixture in a material consisting essentially of a water insoluble polymer selected from the group consisting of ethylcellulose, polyvinyl acetate, polyvinyl chloride and a copolymer of dimethylaminoethyl methacrylate and methyl methacrylate, wherein the encapsulated material is present in an amount that allows bioavailability and which in combination with the basic substance is sufficient to mask the taste of the drug.
Claim 3
Dependent Claim
18 words
A method of preparing a pharmaceutical mixture according to claim 1 wherein the water insoluble polymer is ethylcellulose.
Claim 4
Dependent Claim
38 words
A method according to claim 1, wherein the drug is selected from the group consisting of Bacampicillin, Clobutinolum, Noscapinum, Bromhexidinum, Terbutalinum, Chinidinum, Prometazinum, Diphenhydraminum, Brompheniraminum, Sulfadiazinum, Pivampicillinum, Tetracyclinum, Erythromycinum, Trimethroprim, Dextropropoxyphenum and Chloroquinum or pharmaceutically acceptable salts thereof.
Claim 5
Dependent Claim
85 words
A dry powder produced by the process of claim 1 for use as a pharmaceutical preparation comprising a pharmaceutically acceptable basic substance and a bad tasting drug in a form insoluble at a high pH, both encapsulated in a material consisting essentially of a water insoluble polymer selected from the group consisting of ethyl cellulose, polyvinyl acetate, polyvinyl chloride and a copolymer of dimethylaminoethyl methacrylate and methyl methacrylate, wherein the basic substance is present in a mole ratio of basic substance to drug of 0.2-10.
Claim 6
Dependent Claim
39 words
A dry powder according to claim 4, wherein the drug is selected from the group consisting of bacampicillin, Clobutinolum, Noscapinum, Bromhexidinum, Terbutalinum, Chinidinum, Prometazinum, Diphenhydraminum, Brompheniraminum, Sulfadiazinum, Pivampicillinum, Tetracylinum, Erythromycinum, Trimethoprim, Dextropropoxyphenum, and Chloroquinum, or pharmaceutically acceptable salts thereof.
Claim 7
Dependent Claim
14 words
A dry powder according to claim 4, wherein the basic substance is sodium bicarbonate.
Claim 8
Independent Claim
130 words
A method of preparing a dry powder for use as a pharmaceutical preparation which comprises mixing a pharmaceutically acceptable basic substance selected from the group consisting of sodium bicarbonate, disodium mono hydrogenphosphate, dipotassium hydrogenphosphate, trisodium citrate, magnesium dihydroxide and trizma with a bad tasting drug encapsulated in a material consisting essentially of a water-insoluble polymer selected from the group consisting of ethylcellulose, polyvinyl acetate, polyvinyl chloride and a copolymer of dimethylaminoethyl methacrylate and methylmethacrylate, said drug being present in a form insoluble at high pH, said basic substance being present in a mole ratio of basic substance to drug of 0.2-10, wherein the encapsulated material is present in an amount that allows bioavailability and which in combination with the basic substance is sufficient to mask the taste of the drug.
Claim 9
Independent Claim
130 words
A method of preparing a dry powder for use as a pharmaceutical preparation which comprises mixing a pharmaceutically acceptable basic substance selected from the group consisting of sodium bicarbonate, disodium mono hydrogenphosphate, dipotassium hydrogenphosphate, trisodium citrate, magnesium dihydroxide and trizma with a bad tasting drug encapsulated in a material consisting essentially of a water-insoluble polymer selected from the group consisting of ethylcellulose, polyvinyl acetate, polyvinyl chloride and a copolymer of dimethylaminoethyl methacrylate and methylmethacrylate, said drug being present in a form insoluble at high pH, said basic substance being present in a mole ratio of basic substance to drug of 0.2-10, wherein the encapsulated material is present in an amount that allows bioavailability and which in combination with the basic substance is sufficient to mask the taste of the drug.
Claim 10
Dependent Claim
38 words
A method according to claim 7, wherein the drug is selected from the group consisting of Bacampicillin, Clobutinolum, Noscapinum, Bromhexidinum, Terbutalinum, Chinidinum, Prometazinum, Diphenhydraminum, Brompheniraminum, Sulfadiazinum, Pivampicillinum, Tetracyclinum, Erythromycinum, Trimethroprim, Dextropropoxyphenum and Chloroquinum or pharmaceutically acceptable salts thereof.
Claim 11
Dependent Claim
85 words
A dry powder produced by a process according to claim 7 for use as a pharmaceutical preparation comprising a pharmaceutically acceptable basic substance, and a bad-tasting drug encapsulated in a material consisting essentially of a water-insoluble polymer selected from the group consisting of ethyl cellulose, polyvinyl acetate, polyvinyl chloride, and a copolymer of dimethylaminoethyl methacrylate and methylmethacrylate, wherein the drug is in a form insoluble at high pH, and the basic substance is present in a mole ratio of basic substance to drug of 0.2-10.
Claim 12
Dependent Claim
39 words
A dry powder according to claim 9 wherein the drug is selected from the group consisting of bacampicillin, Clobutinolum, Noscapinum, Bromhexidinum, Terbutalinum, Chinidinum, Prometazinum, Diphenhydraminum, Brompheniraminum, Sulfadiazinum, Pivampicillinum, Tetracyclinum, Erythromycinum, Trimethoprim, Dextropropoxyphenum, and Chloroquinum, or pharmaceutically acceptable salts thereof.
Claim 13
Dependent Claim
14 words
A dry powder according to claim 9 wherein the basic substance is sodium bicarbonate.
References Cited (Backward Citations)
US4101651A
Cited
US4177254A
Cited
US4205060A
Cited
JPS55129224A
Cited
US4261970A
Cited
US4321253A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-04-06 | 1990-10-06 | 1991-04-07 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-04-06 | 1994-10-06 | 1995-04-07 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-04-06 | 1998-10-06 | 1999-04-07 | $7700.00 | Window Closed / Lapsed |